abstract |
Provided is the use of an oxymethylene aryl GPRl 19 agonist, optionally a DPP IV inhibitor, and optionally metformin for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions with nutrient and / or fluid malabsorption. [Selection figure] None |